Recurrent Prostate Cancer and Low PSA Levels: Can an Emerging PSMA PET Agent Have an Impact?
Diagnostic Imaging ,
Use of the prostate-specific membrane antigen (PSMA) positron emission tomography (PET) agent piflufolastat F 18 led to…
Use of the prostate-specific membrane antigen (PSMA) positron emission tomography (PET) agent piflufolastat F 18 led to…
Prostate-specific membrane antigen, or PSMA, has made headlines in the past several years with several important clinical…
At the American Urological Association (AUA) 2022 meeting in New Orleans, the Friday plenary session consisted of several high-yi…
NORTH BILLERICA, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc.